Search Results

21 Results for "viracyte".

Sort By

Drug Development

ViraCyte Announces Positive Phase II Trial Results

August 22, 2017
·
2 min read
Drug Development

ViraCyte Completes Phase I Clinical Trial Of Viralym-C

July 11, 2017
·
2 min read
Lone Star Bio

ViraCyte Awarded $8.99M From The Cancer Prevention And Research Institute Of Texas

August 18, 2017
·
1 min read
Drug Development

ViraCyte Release: Company Receives Orphan Drug Designation For Viralym-C

January 24, 2017
·
2 min read
Genetown

ElevateBio Announces that AlloVir Joins its Portfolio of Highly Innovative Cell and Gene Therapy Companies

ElevateBio, a cell and gene therapy holding company, announced that AlloVir, formerly known as ViraCyte, has joined its growing portfolio of highly innovative companies.

May 22, 2019
·
7 min read
Lone Star Bio

ViraCyte Awarded $3.75 Million From NIH And FDA To Advance T Cell Immunotherapies

July 5, 2017
·
2 min read
Business

ViraCyte Appoints Dr. Brett Giroir As President and Chief Executive Officer

November 29, 2016
·
2 min read
Business

ViraCyte Enters Exclusive License Agreement With Baylor College of Medicine For T Cell Immunotherapies Targeting Viruses

July 18, 2017
·
2 min read
Drug Development

ViraCyte Release: Pharma Granted U.S. FDA Fast Track Designation For Viralym-C

January 10, 2017
·
2 min read
Lone Star Bio

Backed by Gilead, Fidelity and Others, AlloVir Closes on $120 Million Series B Financing

AlloVir is working to develop an allogeneic cell therapy to control infections in immunocompromised patients, typically after they undergo organ transplants.

May 22, 2019
·
3 min read
·
Mark Terry